deltatrials
Completed PHASE1 NCT00065390

Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome

Pilot (Phase I-II) Study of Pyrimethamine (Daraprim) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Autoimmune Disease Lymphatic Disease Lymphoproliferative Disorder
Interventions Pyrimethamine
Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Jul 31, 2003 Completion: Jun 30, 2005

Listed as NCT00065390, this PHASE1 trial focuses on Autoimmune Disease and Lymphatic Disease and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States